Neurokin - Company Profile

Biotechnology Company NEUROKIN Strengthens its Board of Directors and Scientific Committee

The neuroprotective drugs development company announces today the appointment of two former Vice Presidents of Sanofi - Aventis; Bernard Reculeau, and Jesús Benavides.

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

The Company strengthens its intellectual property with the grant of European patent on its most advanced drug candidate NK-102.

Neurokin scientifically recognized with a publication in the PLoS One Revue

The significant results obtained by NEUROKIN were published in August by the PLoS One Revue in an article entitled: « Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models »*. Bénédicte Menn et al., PLoS ONE, August 2010, volume 5, issue 8.

New patent granted to Neurokin by the European Patent Office

Neurokin's patent EP 1 998 778 has been granted.

Neurokin launches updated website

Neurokin launches updated website.

Biotechnology Company NEUROKIN Strengthens its Board of Directors and Scientific Committee

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Neurokin scientifically recognized with a publication in the PLoS One Revue

New patent granted to Neurokin by the European Patent Office

Neurokin launches updated website

Company Profile

History

Mission

People

Featured links